We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

PTAB Nixes Patent For Valeant's Antifungal Jublia

Law360 (June 7, 2018, 10:00 PM EDT) -- The Patent Trial and Appeal Board on Wednesday invalidated the entirety of a Kaken Pharmaceutical Co. patent used to create Valeant Pharmaceuticals International Inc.’s antifungal medication Jublia, finding that it had been anticipated by a series of prior art.

The board said neither of U.S. Patent Number 7,214,506’s two claims could survive the challenge brought by generic drugmakers Acrux DDS Pty Ltd. and Argentum Pharmaceuticals LLC.

The final written decision notes that several pieces of prior art focus on using topical treatments on nails to treat...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.